Competitive repopulation of TSC-22+/+ and TSC-22−/− bone marrow cells
| Recipient mice* . | Donor bone marrow cells . | Percentage engraftment by donor cells (no. of mice) . | Notes . | |
|---|---|---|---|---|
| 3 months . | 6 months . | |||
| WT CD45.2 | TSC-22+/+ CD45.1 | 93.1 ± 2.0 (4) | 96.6 ± 0.4 (3) | Control |
| WT CD45.1 | TSC-22+/+ CD45.2 | 91.9 ± 2.0 (15) | 96.6 ± 1.1 (15) | Control |
| WT CD45.1 | TSC-22−/− CD45.2 | 91.6 ± 2.2 (15) | 96.2 ± 2.1 (15) | Control |
| WT CD45.1 | 50% TSC-22−/− CD45.2: 50% TSC-22+/+ CD45.1 | 64.5 ± 4.1 (12)† | 73.7 ± 5.8 (10)† | Experimental |
| 70.0 ± 5.4 | 76.4 ± 6.3 | Experimental and normalized‡ | ||
| 1.40 | 1.53 | Experimental ratio of normalized engraftment to expected engraftment§ | ||
| ≥ 2.33 | ≥ 3.24 | Experimental ratio of normalized TSC-22−/− engraftment to actual engraftment of TSC-22+/+‖ | ||
| Recipient mice* . | Donor bone marrow cells . | Percentage engraftment by donor cells (no. of mice) . | Notes . | |
|---|---|---|---|---|
| 3 months . | 6 months . | |||
| WT CD45.2 | TSC-22+/+ CD45.1 | 93.1 ± 2.0 (4) | 96.6 ± 0.4 (3) | Control |
| WT CD45.1 | TSC-22+/+ CD45.2 | 91.9 ± 2.0 (15) | 96.6 ± 1.1 (15) | Control |
| WT CD45.1 | TSC-22−/− CD45.2 | 91.6 ± 2.2 (15) | 96.2 ± 2.1 (15) | Control |
| WT CD45.1 | 50% TSC-22−/− CD45.2: 50% TSC-22+/+ CD45.1 | 64.5 ± 4.1 (12)† | 73.7 ± 5.8 (10)† | Experimental |
| 70.0 ± 5.4 | 76.4 ± 6.3 | Experimental and normalized‡ | ||
| 1.40 | 1.53 | Experimental ratio of normalized engraftment to expected engraftment§ | ||
| ≥ 2.33 | ≥ 3.24 | Experimental ratio of normalized TSC-22−/− engraftment to actual engraftment of TSC-22+/+‖ | ||
Wild-type (WT) recipient mice were lethally irradiated.
Percentage of TSC-22−/− CD45.2 engrafted cells.
“Normalized” represents the ratio of the engrafted CD45.2 TSC-22−/− percentage to the average of donor cell percentages in 3 control experiments (eg, the average of 93.1%, 91.9%, and 91.6% for 3 months).
The “expected” engraftment would be 50% as it assumes no difference in repopulation efficiency between TSC-22−/− and TSC-22+/+ bone marrow cells (eg, 70%:50% = 1.40 at 3 months).
Actual engraftment of TSC-22+/+ at 3 months is 100% − 70% = 30%; 23.6% at 6 months.